Flash FinanceUS
Market closed S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · CVS Health (CVS)

CVS Health adds four directors under confidentiality pact with Glenview Capital

Neutral Impact 4 of 5 leadership Written later

CVS Health increased its board from 12 to 16 members on November 17, 2024, appointing Leslie Norwalk, Larry Robbins, Guy Sansone and Doug Shulman, after discussions with activist investor Glenview Capital Management. The company also entered a confidentiality agreement with Glenview that includes customary standstill and non-disparagement terms, and the filing describes compensation changes for two senior executives.

Key points

  • Board expanded from 12 to 16 members; Norwalk, Robbins, Sansone and Shulman appointed November 17, 2024
  • Company agreed to nominate all four for election at the 2025 annual meeting of stockholders
  • Glenview standstill restrictions remain in effect until 30 days before the stockholder nomination window for the 2026 annual meeting
  • Premium-priced stock options with grant date values of $12,000,000 for CEO J. David Joyner and $6,000,000 for Prem S. Shah, granted November 30, 2024

The filing

CompanyCVS Health (CVS)
Form8-K, current report
Filed with the SECNov 18, 2024, 6:45 AM ET
Accession number0001193125-24-260405

Items reported: 1.01 Material Definitive Agreement5.02 Director / Officer Change7.01 Regulation FD Disclosure

Read the filing on SEC.gov ↗

Written by AI (Anthropic Claude, claude-haiku-5-5) on Nov 8, 2026, 1:21 AM ET, from the text of the filing and its press-release exhibits only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on November 18, 2024.

Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.